Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 19/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.62 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038541 | 0.92 | CACNA1B (1.00) | CACNA1BCYP3A4NR1I2SLC6A9 | |
| SCHEMBL3038628 | 0.88 | CACNA1B (0.77) | CACNA1BCYP3A4NR1I2 | |
| SCHEMBL14701468 | 0.86 | CACNA1B (0.65) | CACNA1BCYP3A4NR1I2 | |
| SCHEMBL3032066 | 0.84 | CACNA1B (0.72) | CACNA1BCYP3A4NR1I2 | |
| SCHEMBL3035805 | 0.83 | CACNA1B (0.84) | CACNA1BCYP3A4NR1I2SLC6A9 | |
| SCHEMBL3039198 | 0.82 | CACNA1B (0.81) | CACNA1BCYP3A4NR1I2SLC6A9 | |
| SCHEMBL3040527 | 0.81 | CACNA1B (0.75) | CACNA1BCYP3A4NR1I2 | |
| SCHEMBL3035326 | 0.80 | CACNA1B (0.77) | CACNA1BCYP3A4NR1I2 | |
| SCHEMBL3039751 | 0.80 | CACNA1B (0.66) | CACNA1BCYP3A4NR1I2 | |
| SCHEMBL3032407 | 0.79 | CACNA1B (0.77) | CACNA1BCYP3A4NR1I2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.